Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-04-08

AUTHORS

Andrea Kuendgen, Gesine Bug, Oliver G. Ottmann, Detlef Haase, Julie Schanz, Barbara Hildebrandt, Kathrin Nachtkamp, Judith Neukirchen, Ariane Dienst, Rainer Haas, Ulrich Germing, Norbert Gattermann

ABSTRACT

5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZA (100 mg/m2, 5 days) plus valproate (VPA; continuous dosing, trough serum level 80–110 μg/ml). According to WHO classification, 5 patients had MDS, 2 had MDS/MPD, and 17 had acute myeloid leukemia (AML). Seven patients (29%) had previously received intensive chemotherapy, and five had previous HDAC inhibitor treatment. The overall response rate was 37% in the entire cohort but significantly higher (57%) in previously untreated patients, especially those with MDS (64%). Seven (29%) patients achieved CR (29%) and two PR (8%), respectively. Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34+ peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. Four additional patients achieved at least marrow remissions. Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. This trial is the first to assess the combination of AZA plus VPA without additional ATRA. A comparatively good CR rate, relatively short time to response, and the influence of VPA serum levels on response suggest that VPA provided substantial additional benefit. However, the importance of HDAC inhibitors in epigenetic combination therapy can only be proven by randomized trials. More... »

PAGES

389-399

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9

DOI

http://dx.doi.org/10.1007/s13148-011-0031-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034458391

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22704349


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuendgen", 
        "givenName": "Andrea", 
        "id": "sg:person.01022105364.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7839.5", 
          "name": [
            "Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bug", 
        "givenName": "Gesine", 
        "id": "sg:person.0660354231.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660354231.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7839.5", 
          "name": [
            "Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ottmann", 
        "givenName": "Oliver G.", 
        "id": "sg:person.01051501512.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haase", 
        "givenName": "Detlef", 
        "id": "sg:person.0754465332.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schanz", 
        "givenName": "Julie", 
        "id": "sg:person.01252562364.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252562364.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Human Genetics, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institute of Human Genetics, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hildebrandt", 
        "givenName": "Barbara", 
        "id": "sg:person.01320675564.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nachtkamp", 
        "givenName": "Kathrin", 
        "id": "sg:person.01367010764.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367010764.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neukirchen", 
        "givenName": "Judith", 
        "id": "sg:person.0643404664.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dienst", 
        "givenName": "Ariane", 
        "id": "sg:person.0673303715.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673303715.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "Rainer", 
        "id": "sg:person.01127414674.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2404796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003666698", 
          "https://doi.org/10.1038/sj.leu.2404796"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04-08", 
    "datePublishedReg": "2011-04-08", 
    "description": "Abstract5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZA (100\u00a0mg/m2, 5\u00a0days) plus valproate (VPA; continuous dosing, trough serum level 80\u2013110\u00a0\u03bcg/ml). According to WHO classification, 5 patients had MDS, 2 had MDS/MPD, and 17 had acute myeloid leukemia (AML). Seven patients (29%) had previously received intensive chemotherapy, and five had previous HDAC inhibitor treatment. The overall response rate was 37% in the entire cohort but significantly higher (57%) in previously untreated patients, especially those with MDS (64%). Seven (29%) patients achieved CR (29%) and two PR (8%), respectively. Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34+ peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. Four additional patients achieved at least marrow remissions. Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. This trial is the first to assess the combination of AZA plus VPA without additional ATRA. A comparatively good CR rate, relatively short time to response, and the influence of VPA serum levels on response suggest that VPA provided substantial additional benefit. However, the importance of HDAC inhibitors in epigenetic combination therapy can only be proven by randomized trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13148-011-0031-9", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1042271", 
        "issn": [
          "1868-7075", 
          "1868-7083"
        ], 
        "name": "Clinical Epigenetics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "acute myeloid leukemia", 
      "myelodysplastic syndrome", 
      "epigenetic combination therapy", 
      "serum levels", 
      "combination therapy", 
      "myeloid leukemia", 
      "response rate", 
      "poor\u2010risk myelodysplastic syndromes", 
      "high-risk myelodysplastic syndrome", 
      "valproic acid serum levels", 
      "bone marrow mononuclear cells", 
      "better CR rate", 
      "VPA serum levels", 
      "marrow blast count", 
      "overall response rate", 
      "histone deactylase inhibitors", 
      "complete cytogenetic remission", 
      "MDS/MPD", 
      "peripheral blood cells", 
      "HDAC inhibitor treatment", 
      "marrow mononuclear cells", 
      "hematological CR", 
      "intensive chemotherapy", 
      "untreated patients", 
      "complete remission", 
      "marrow remission", 
      "concomitant medications", 
      "blast count", 
      "cytogenetic remission", 
      "additional patients", 
      "transfusion dependency", 
      "CR rate", 
      "randomized trials", 
      "entire cohort", 
      "evaluable cases", 
      "standard treatment", 
      "mononuclear cells", 
      "combination of azacytidine", 
      "response duration", 
      "substantial additional benefit", 
      "valproic acid", 
      "patients", 
      "inhibitor treatment", 
      "HDAC inhibitors", 
      "remission", 
      "mitochondrial DNA mutations", 
      "blood cells", 
      "somatic mitochondrial DNA mutations", 
      "conventional cytogenetics", 
      "azacytidine", 
      "syndrome", 
      "therapy", 
      "leukemia", 
      "treatment", 
      "VPA", 
      "trials", 
      "additional benefit", 
      "DNA mutations", 
      "inhibitors", 
      "valproate", 
      "cells", 
      "response", 
      "medications", 
      "chemotherapy", 
      "cohort", 
      "CD34", 
      "ATRA", 
      "rate", 
      "levels", 
      "hydroxyurea", 
      "duration", 
      "count", 
      "cytogenetics", 
      "pretreatment", 
      "mutations", 
      "combination", 
      "short time", 
      "factors", 
      "cases", 
      "benefits", 
      "attractive partners", 
      "acid", 
      "MPD", 
      "partners", 
      "PR", 
      "classification", 
      "time", 
      "importance", 
      "fish", 
      "Cr", 
      "influence", 
      "dependency"
    ], 
    "name": "Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid", 
    "pagination": "389-399", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034458391"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13148-011-0031-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22704349"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13148-011-0031-9", 
      "https://app.dimensions.ai/details/publication/pub.1034458391"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_541.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13148-011-0031-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      21 PREDICATES      119 URIs      109 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13148-011-0031-9 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 anzsrc-for:1112
4 schema:author N10c9adee7c7f4a0d80bbb536d23fb987
5 schema:citation sg:pub.10.1038/sj.leu.2404796
6 schema:datePublished 2011-04-08
7 schema:datePublishedReg 2011-04-08
8 schema:description Abstract5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZA (100 mg/m2, 5 days) plus valproate (VPA; continuous dosing, trough serum level 80–110 μg/ml). According to WHO classification, 5 patients had MDS, 2 had MDS/MPD, and 17 had acute myeloid leukemia (AML). Seven patients (29%) had previously received intensive chemotherapy, and five had previous HDAC inhibitor treatment. The overall response rate was 37% in the entire cohort but significantly higher (57%) in previously untreated patients, especially those with MDS (64%). Seven (29%) patients achieved CR (29%) and two PR (8%), respectively. Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34+ peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. Four additional patients achieved at least marrow remissions. Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. This trial is the first to assess the combination of AZA plus VPA without additional ATRA. A comparatively good CR rate, relatively short time to response, and the influence of VPA serum levels on response suggest that VPA provided substantial additional benefit. However, the importance of HDAC inhibitors in epigenetic combination therapy can only be proven by randomized trials.
9 schema:genre article
10 schema:isAccessibleForFree true
11 schema:isPartOf N1b48774896f54541b4b0f1dbcd09ca8e
12 Nfc524190f0b543af8a42d6dda8ba975d
13 sg:journal.1042271
14 schema:keywords ATRA
15 CD34
16 CR rate
17 Cr
18 DNA mutations
19 HDAC inhibitor treatment
20 HDAC inhibitors
21 MDS/MPD
22 MPD
23 PR
24 VPA
25 VPA serum levels
26 acid
27 acute myeloid leukemia
28 additional benefit
29 additional patients
30 attractive partners
31 azacytidine
32 benefits
33 better CR rate
34 blast count
35 blood cells
36 bone marrow mononuclear cells
37 cases
38 cells
39 chemotherapy
40 classification
41 cohort
42 combination
43 combination of azacytidine
44 combination therapy
45 complete cytogenetic remission
46 complete remission
47 concomitant medications
48 conventional cytogenetics
49 count
50 cytogenetic remission
51 cytogenetics
52 dependency
53 duration
54 entire cohort
55 epigenetic combination therapy
56 evaluable cases
57 factors
58 fish
59 hematological CR
60 high-risk myelodysplastic syndrome
61 histone deactylase inhibitors
62 hydroxyurea
63 importance
64 influence
65 inhibitor treatment
66 inhibitors
67 intensive chemotherapy
68 leukemia
69 levels
70 marrow blast count
71 marrow mononuclear cells
72 marrow remission
73 medications
74 mitochondrial DNA mutations
75 mononuclear cells
76 mutations
77 myelodysplastic syndrome
78 myeloid leukemia
79 overall response rate
80 partners
81 patients
82 peripheral blood cells
83 poor‐risk myelodysplastic syndromes
84 pretreatment
85 randomized trials
86 rate
87 remission
88 response
89 response duration
90 response rate
91 serum levels
92 short time
93 somatic mitochondrial DNA mutations
94 standard treatment
95 substantial additional benefit
96 syndrome
97 therapy
98 time
99 transfusion dependency
100 treatment
101 trials
102 untreated patients
103 valproate
104 valproic acid
105 valproic acid serum levels
106 schema:name Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
107 schema:pagination 389-399
108 schema:productId N9baf3a28e6884197a104c6e75baece5a
109 Nae125ed8a90f4111b53e91a98190e810
110 Nb676e5bf4afc492fa7b13c8fd06b6267
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034458391
112 https://doi.org/10.1007/s13148-011-0031-9
113 schema:sdDatePublished 2022-08-04T17:00
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Nbc01a5afcfc14da6a66f8a2d7f657322
116 schema:url https://doi.org/10.1007/s13148-011-0031-9
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N10c9adee7c7f4a0d80bbb536d23fb987 rdf:first sg:person.01022105364.01
121 rdf:rest N47990c72fb6843ec842fbdeda3e33db2
122 N1ab849f488784cb9bb44d32fc564e6be rdf:first sg:person.01273447501.34
123 rdf:rest rdf:nil
124 N1b48774896f54541b4b0f1dbcd09ca8e schema:issueNumber 2
125 rdf:type schema:PublicationIssue
126 N47990c72fb6843ec842fbdeda3e33db2 rdf:first sg:person.0660354231.27
127 rdf:rest Ne3ab05cea1d14ff594be51c90d7968c6
128 N4cd9ad66173f4536ba840c6c070375fa rdf:first sg:person.0643404664.08
129 rdf:rest N736c6868742444c9b1504c55316173cd
130 N5432a9f6c49f41a9b2af40c0c4b09f0a rdf:first sg:person.01320675564.15
131 rdf:rest Nbbb0f9814f4e42f790a611275ae2d2c4
132 N5ef5435a42c3481b8e21de66f760893e rdf:first sg:person.01252562364.34
133 rdf:rest N5432a9f6c49f41a9b2af40c0c4b09f0a
134 N72206512e5f54c76b8f88eb7970bb829 rdf:first sg:person.01362464041.20
135 rdf:rest N1ab849f488784cb9bb44d32fc564e6be
136 N736c6868742444c9b1504c55316173cd rdf:first sg:person.0673303715.21
137 rdf:rest Na6a99d018ddf4f839d1bde5197706cdd
138 N9baf3a28e6884197a104c6e75baece5a schema:name pubmed_id
139 schema:value 22704349
140 rdf:type schema:PropertyValue
141 Na6a99d018ddf4f839d1bde5197706cdd rdf:first sg:person.01127414674.14
142 rdf:rest N72206512e5f54c76b8f88eb7970bb829
143 Nae125ed8a90f4111b53e91a98190e810 schema:name doi
144 schema:value 10.1007/s13148-011-0031-9
145 rdf:type schema:PropertyValue
146 Nb676e5bf4afc492fa7b13c8fd06b6267 schema:name dimensions_id
147 schema:value pub.1034458391
148 rdf:type schema:PropertyValue
149 Nbbb0f9814f4e42f790a611275ae2d2c4 rdf:first sg:person.01367010764.53
150 rdf:rest N4cd9ad66173f4536ba840c6c070375fa
151 Nbc01a5afcfc14da6a66f8a2d7f657322 schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 Nc1f97ec0bc084293bb2d7940ca12ac7c rdf:first sg:person.0754465332.53
154 rdf:rest N5ef5435a42c3481b8e21de66f760893e
155 Ne3ab05cea1d14ff594be51c90d7968c6 rdf:first sg:person.01051501512.14
156 rdf:rest Nc1f97ec0bc084293bb2d7940ca12ac7c
157 Nfc524190f0b543af8a42d6dda8ba975d schema:volumeNumber 2
158 rdf:type schema:PublicationVolume
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
163 schema:name Cardiorespiratory Medicine and Haematology
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
166 schema:name Oncology and Carcinogenesis
167 rdf:type schema:DefinedTerm
168 sg:journal.1042271 schema:issn 1868-7075
169 1868-7083
170 schema:name Clinical Epigenetics
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.01022105364.01 schema:affiliation grid-institutes:grid.411327.2
174 schema:familyName Kuendgen
175 schema:givenName Andrea
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01
177 rdf:type schema:Person
178 sg:person.01051501512.14 schema:affiliation grid-institutes:grid.7839.5
179 schema:familyName Ottmann
180 schema:givenName Oliver G.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14
182 rdf:type schema:Person
183 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
184 schema:familyName Haas
185 schema:givenName Rainer
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
187 rdf:type schema:Person
188 sg:person.01252562364.34 schema:affiliation grid-institutes:grid.7450.6
189 schema:familyName Schanz
190 schema:givenName Julie
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252562364.34
192 rdf:type schema:Person
193 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
194 schema:familyName Gattermann
195 schema:givenName Norbert
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
197 rdf:type schema:Person
198 sg:person.01320675564.15 schema:affiliation grid-institutes:grid.411327.2
199 schema:familyName Hildebrandt
200 schema:givenName Barbara
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15
202 rdf:type schema:Person
203 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
204 schema:familyName Germing
205 schema:givenName Ulrich
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
207 rdf:type schema:Person
208 sg:person.01367010764.53 schema:affiliation grid-institutes:grid.411327.2
209 schema:familyName Nachtkamp
210 schema:givenName Kathrin
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367010764.53
212 rdf:type schema:Person
213 sg:person.0643404664.08 schema:affiliation grid-institutes:grid.411327.2
214 schema:familyName Neukirchen
215 schema:givenName Judith
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08
217 rdf:type schema:Person
218 sg:person.0660354231.27 schema:affiliation grid-institutes:grid.7839.5
219 schema:familyName Bug
220 schema:givenName Gesine
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660354231.27
222 rdf:type schema:Person
223 sg:person.0673303715.21 schema:affiliation grid-institutes:grid.411327.2
224 schema:familyName Dienst
225 schema:givenName Ariane
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673303715.21
227 rdf:type schema:Person
228 sg:person.0754465332.53 schema:affiliation grid-institutes:grid.7450.6
229 schema:familyName Haase
230 schema:givenName Detlef
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53
232 rdf:type schema:Person
233 sg:pub.10.1038/sj.leu.2404796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003666698
234 https://doi.org/10.1038/sj.leu.2404796
235 rdf:type schema:CreativeWork
236 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
237 Institute of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany
238 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
239 Institute of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany
240 rdf:type schema:Organization
241 grid-institutes:grid.7450.6 schema:alternateName Department of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany
242 schema:name Department of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany
243 rdf:type schema:Organization
244 grid-institutes:grid.7839.5 schema:alternateName Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany
245 schema:name Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...